Скачать или смотреть Novartis Acquires Avidity Biosciences: A $12 Billion Deal

Novartis AG has agreed to acquire Avidity Biosciences, a biopharmaceutical company, for $12 billion in cash. The deal includes a spin-off of Avidity's early-stage precision cardiology programs into a new company, SpinCo, which will focus on rare genetic cardiomyopathies. The acquisition provides Novartis with access to Avidity's RNA-targeting delivery platform and three late-stage clinical development programs for rare muscle diseases. The transaction is expected to close in the first half of 2026, subject to regulatory approvals and customary closing conditions. This video explores the strategic implications of the deal for both companies and the potential impact on the RNA therapeutics market.